Subreddits like r/Peptides and r/PeptideGuide evaluate vendors based on third-party COA availability, response to community-sourced independent testing, shipping consistency, customer service transparency, and history of no bait-and-switch product reformulations
Some individuals may be relative "non-responders" at lower doses but achieve satisfactory results with dose escalation
Cortisol elevation is problematic because chronic cortisol excess promotes muscle breakdown, fat storage, immune suppression, and sleep disruption the opposite of what individuals seeking GH optimization want
Its not uncommon to see this progression of DR if we improve glucose control, said Rishi P
Qualifying reasons under 503A include: Allergy to phenol or another preservative in the commercial formulation Need for a dose strength not commercially available (e.g., 1.5 mg, which falls between Ozempic's 1 mg and 2 mg pens) Inability to use the pen injector device due to dexterity issues (though this is weak because vial-and-syringe versions could theoretically be requested from Novo Nordisk) The FDA has historically taken a narrow view of what constitutes a legitimate patient-specific need, and "I prefer the compounded version" or "the commercial version is too expensive" do not qualify
8 , bvae111 (2024)